Shares of Caplin Point Laboratories Ltd were trading 1% higher during the early trading hours but crashed 5% on 17 November after the company received an adverse regulatory update, after the US Food and Drug Administration (USFDA) classified the inspection of its subsidiary Caplin Steriles’ Gummidipoondi manufacturing facility as Official Action Indicated (OAI).
The development follows an inspection conducted between 13 August 2026 and 21 August 2026, which resulted in 10 observations. The company received the FDA’s classification communication on 16 November 2026 and disclosed the development to stock exchanges on 17 November 2026.
The inspection covered Caplin Steriles’ injectable and ophthalmic manufacturing facility in Gummidipoondi, Tamil Nadu. At the end of the inspection, the company received Form FDA 483 containing 10 observations.
According to Caplin Point, the observations were procedural in nature, did not involve data integrity issues and were not repeat observations.
However, the FDA subsequently assigned the inspection an OAI classification. Under FDA guidelines, OAI means the facility has been found in an unacceptable state of compliance and regulatory or administrative action may be recommended. This is more serious than a Voluntary Action Indicated (VAI) classification.
Caplin Point said it does not expect any material impact on its financials or operations as of 17 November 2026. The Gummidipoondi facility continues to manufacture and supply products.
The company has also committed to working with the USFDA to address the observations through corrective and preventive actions and demonstrate that the improvements are effective and sustainable.
Although there is no immediate material disruption reported, the OAI status could create challenges for future product approvals involving the facility until regulatory concerns are resolved.
At 3:20 pm, the shares of Caplin Point were trading 5.25% lower at Rs 2,223.40 on NSE.
Not sure when to enter—or when to exit? Get defined trade levels and live follow-up updates from a SEBI-registered Research Analyst. Download the IDT app today. https://idt.equitypandit.in/
Live
